BioClinica Unveils Platform for Integrated Clinical Operations Based on Microsoft Technologies

BioClinica Unveils Platform for Integrated Clinical Operations Based on Microsoft Technologies

 
- Will Demonstrate eClinical Technology Innovation at 46th DIA Annual Meeting, June 13-17 -

NEWTOWN, Pa.--(BUSINESS WIRE)--BioClinicaTM, Inc., (NASDAQ: BIOC), a global provider of clinical trial management services, will exhibit at the 46th Drug Information Association (DIA) Annual Meeting from June 13-17, 2010 in Washington, D.C., where it will showcase the BioClinica eClinical Technology Suite as well as introduce the BioClinica Integrated Operations Platform (BIOP). This advancement in clinical support technology leverages the power, the familiarity, and the ubiquity of Microsoft Office and SharePoint platforms to deliver a real world window on clinical operations -- across studies and across clinical technologies.

"We are eager to share details about our integration with the Microsoft platform during the DIA, as we believe it represents the future of clinical information accessibility"

This far-reaching development will enable BioClinica to make mission-critical operational data accessible in Microsoft Office and SharePoint applications that most customers already use.

"We are eager to share details about our integration with the Microsoft platform during the DIA, as we believe it represents the future of clinical information accessibility," said Mark Weinstein, CEO of BioClinica. "Our customers told us that they needed a simpler way to centralize and share their operational data for managing clinical trials. Through our work with Microsoft we are embracing the SharePoint and Office tools that many customers already have and use. Unlike other solutions, this platform untethers the clinical data, making the data more easily accessible and therefore more usable."

SharePoint is one of the fastest growing server products in Microsoft history, with more than 100 million licenses sold. The platform delivers increased workflow efficiencies among life sciences colleagues, partners and customers. At DIA, BioClinica will feature its full-service eClinical suite, including the BioClinica Clinical Trial Management System (CTMS). BioClinica CTMS utilizes SharePoint, creating customer oversight to eClinical workflow and access to data and reports through the Microsoft Office platform.

"To keep up with market demands, life sciences companies are under increased pressure to speed the pace of clinical trials and quickly bring new drugs to market," said Michael Naimoli, director of life sciences industry solutions, Microsoft. "With the integration of our Office and SharePoint platforms, BioClinica customers can liberate their data for a comprehensive, real-time view into studies and pertinent information, with Office Smart clinical trial management systems."

Learn more about BioClinica and their Microsoft integration by visiting the BioClinica booth (#111) or at the Microsoft booth (#711).

ABOUT THE DIA ANNUAL MEETING

The DIA Annual Meeting is the premier event for professionals involved in the discovery, development, and life cycle management of pharmaceuticals, medical devices, and related products. There is no other industry meeting of its kind that can rival the breadth and depth of experience that this meeting delivers. With 25 content-area tracks, 330 sessions, and 20 tutorials, presentations are geared to attendees at all disciplines, works settings, and experience levels.

About BioClinica, Inc.

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management services. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, Microsoft Office-Smart clinical trial management, and clinical supply chain forecasting and optimization solutions. BioClinica services maximize efficiency and manageability throughout all phases of the clinical trial process. With more than 20 years of experience and over 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."